FENC — FENNEC PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1211583 ·
Last close
$13.45
Market Cap
$474.85M
52W High
$13.85
52W Low
$5.65
ADV30
234,984
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 19,608,000 | 18,770,000 | 4,654,000 | 4,640,000 | 83,543,000 | 48,684,000 | 34,353,000 |
| Jun 2026 | 17,874,000 | 17,153,000 | 1,737,000 | 1,973,000 | 75,753,000 | 41,249,000 | 33,311,000 |
| Mar 2026 | 15,108,000 | 14,538,000 | -119,000 | 201,000 | 71,822,000 | 40,179,000 | 34,147,000 |
| Dec 2025 | 13,777,000 | 12,013,000 | -2,580,000 | -4,787,000 | 70,551,000 | 36,788,000 | 35,079,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,040,000
Investing CF
—
Financing CF
$24,584,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-227,248,000
Inventory
$2,374,000
Receivables
$23,266,000
ST Investments
—
EBIT TTM
$-2,199,000
Pretax Income TTM
$-3,103,000
Interest Exp TTM
$904,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$66,367,000
EBITDA
$3,820,667
Free Cash Flow
$4,055,125
Enterprise Value
$361,561,472
Total Cash
$48,684,000
Total Debt
$0
Shares Out
35,305,117
Trailing EPS
$-0.13
Book Value
$1.40
ROE
9.1%
ROA
3.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 44,642,000 | -6,346,000 | -9,741,000 | 70,551,000 | 35,079,000 | 35,472,000 | -12,473,000 |
| Dec 2024 | 47,538,000 | 2,479,000 | -436,000 | 44,946,000 | 50,818,000 | -5,872,000 | 26,980,000 |
| Dec 2023 | 21,252,000 | -13,058,000 | -16,045,000 | 26,864,000 | 38,486,000 | -11,622,000 | -17,143,000 |
| Dec 2022 | 1,535,000 | -22,738,000 | -23,714,000 | 26,939,000 | 29,508,000 | -2,569,000 | -18,058,000 |
TTM Snapshot
Revenues TTM
$59,221,000
NetIncome TTM
$-3,250,000
OpCashFlow TTM
—
Assets (Latest)
$75,753,000
Forward EPS
$1.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | $474.76M | $7.18 | — |
| VALN | Valneva SE | $508.73M | $5.36 | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $442.34M | $8.20 | — |
| IRLA | IRulya Therapeutics Inc. | $433.01M | $39.94 | — |
| SANA | Sana Biotechnology, Inc. | $521.36M | $1.74 | — |
News headlines (Yahoo Finance, 1h cache)
Adherex Technologies Q3 Earnings Call Highlights
2026-11-12 17:15 · Yahoo
Fennec Pharma (FENC) Q3 2026 Earnings Call Transcript
2026-11-12 16:31 · Yahoo
Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 11:03 · Yahoo
Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
2026-11-06 10:50 · Yahoo
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
2026-09-17 11:30 · Yahoo
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ...
2026-08-11 21:02 · Yahoo
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates
2026-08-11 14:20 · Yahoo
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 11:01 · Yahoo
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
2026-08-05 11:01 · Yahoo
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-06-22 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.